1. Challenges faced when identifying patients for combination immunotherapy. (August 2017) Authors: Ernstoff, Marc S; Gandhi, Shipra; Pandey, Manu; Puzanov, Igor; Grivas, Petros; Montero, Alberto; Velcheti, Vamsidhar; Turk, Mary Jo; Diaz-Montero, Claudia Marcela; Lewis, Lionel D; Morrison, Carl Journal: Future oncology Issue: Volume 13:Number 18(2017) Page Start: 1607 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Mechanism‐based treatment of cancer with immune checkpoint inhibitor therapies. Issue 9 (12th May 2020) Authors: Abdou, Yara; Pandey, Manu; Sarma, Maithreyi; Shah, Shrunjal; Baron, Jeffrey; Ernstoff, Marc S. Journal: British journal of clinical pharmacology Issue: Volume 86:Issue 9(2020) Page Start: 1690 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Metastatic sarcomatoid renal cell carcinoma treated with immune checkpoint inhibitors. (3rd August 2019) Authors: Hanif, Ahmad; Pandey, Manu; Khan, Sumera; Attwood, Kristopher; George, Saby Journal: Oncoimmunology Issue: Volume 8:Number 8(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Multicenter evaluation of efficacy and toxicity of venetoclax‐based combinations in patients with accelerated and blast phase myeloproliferative neoplasms. Issue 1 (29th October 2021) Authors: King, Amber C.; Weis, Taylor M.; Derkach, Andriy; Ball, Somedeb; Pandey, Manu; Mauro, Michael J.; Goldberg, Aaron D.; Stahl, Maximilian; Famulare, Christopher; Tallman, Martin S.; Wang, Eunice S.; Kuykendall, Andrew T.; Rampal, Raajit K. Journal: American journal of hematology Issue: Volume 97:Issue 1(2022) Page Start: E7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗